

NEXT SCIENCE®

Full Year Results Investor Briefing

Sydney, Australia, Thursday, 24 February 2022 Next Science Limited (ASX:NXS) (**Company**) advises that Next Science's Managing Director, Judith Mitchell, will host an investor conference call and webcast at **10.00am** (Sydney time) on **Monday, 28 February 2022** to discuss the Company's results for the full year ended 31 December 2021. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

<http://apac.directeventreg.com/registration/event/4275445>

To register to participate via webcast, please use the following link:

<https://webcast.openbriefing.com/8438/>

Approved and authorised by Judith Mitchell, Managing Director, Next Science Limited.

Further information:

Judith Mitchell

Managing Director, Next Science Limited

Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm based infections in human health. XBIO is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO technology. Website: www.nextscience.com.